The Mediator head module stimulates basal RNA polymerase II (Pol II) transcription and enables transcriptional regulation. Here we show that the head subunits Med8, Med18 and Med20 form a subcomplex (Med8/18/20) with two submodules. The highly conserved N-terminal domain of Med8 forms one submodule that binds the TATA box-binding protein (TBP) in vitro and is essential in vivo. The second submodule consists of the C-terminal region of Med8 (Med8C), Med18 and Med20. X-ray analysis of this submodule reveals that Med18 and Med20 form related b-barrel folds. A conserved putative protein-interaction face on the Med8C/18/20 submodule includes sites altered by srb mutations, which counteract defects resulting from Pol II truncation. Our results and published data support a positive role of the Med8/18/20 subcomplex in initiation-complex formation and suggest that the Mediator head contains a multipartite TBP-binding site that can be modulated by transcriptional activators.
coexpressed with Med18 D109-140 and Med20 using a tricistronic vector in Escherichia coli (Fig. 1) . A Med8 fragment comprising residues 190-210 was sufficient for copurification of the Med18/20 heterodimer. The resulting stoichiometric trimeric complex between Med8 190-210 , Med18 D109-140 and Med20 (Med8C/18/20) crystallized under different conditions and in a different space group than did the Med18/20 heterodimer (Methods). The structure was solved by molecular replacement with the Med18/20 structure and was refined to a free R-factor of 27.2% at 2.7-Å resolution.
Overall Med8C/18/20 structure Med18 and Med20 form a heterodimer with pseudo two-fold symmetry (Fig. 2) . Med18 consists of an eight-stranded b-barrel with a central pore and three flanking helices (Fig 2a) . Med20 adopts a very similar fold but contains an additional helix at the C terminus, which fills the central pore of its barrel fold (helix aC, Fig. 2a ). The Med20 barrel is open on one side, as if helix aC forms a wedge. The Med18-Med20 interaction is mainly hydrophobic and involves the a2 helices of both subunits and the b5 strands at the opening of the Med20 barrel ( Fig. 2a and Supplementary Table 1 online). The very extended heterodimer interface (3,900 Å 2 buried surface area) explains why the Med18-Med20 interaction was readily detected by various techniques 9, 10, 18, 19 . The C-terminal region of Med8 forms an a-helix that binds across the top of the Med18 barrel, mainly through extensive hydrophobic contacts (Fig. 2a , orange, and Supplementary Table 2 online). Binding of the Med8 helix causes local ordering of Med18 loops but otherwise does not change the free Med18/20 structure. The overall structure of the Med8C/18/20 complex is apparently conserved, as hydrophobic core residues are identical or similar from yeast to human (Fig. 1) , and many residues in the subunit-subunit interfaces are also conserved ( Supplementary Fig. 2 online).
Med18 resembles phosphoryl transfer enzymes
Comparison of the Med18 structure with known folds 20 identified Cet1, the triphosphatase in the yeast mRNA capping apparatus (PDB entry 1D8I) 21 , and two proteins of unknown function from Pyrococcus furiosus (PDB entry 1YEM, Fig. 3a ) and Vibrio parahaemolyticus (PDB entry 2ACA). A BLAST search with sequences of the two latter proteins revealed close similarity (45% and 67% for 1YEM and 2ACA, respectively) with adenylate cyclase-2 of Aeromonas hydrophila 22 , identifying 1YEM and 2ACA as putative adenylate cyclases. Both putative cyclases contain a CYTH domain with a conserved N-terminal ExExK motif (where x is any residue) 23 . This motif is also found in Cet1 and forms a b-strand at the same location in all structures (Fig. 3b) . The side chains of the two glutamates and the lysine in the ExExK motif protrude into the pore (Fig. 3b) glutamates bind a catalytic metal ion in Cet1 (ref. 21) , and the lysine binds a phosphate ion in the 2ACA structure. A second phosphate ion is bound in the 2ACA structure by conserved residues outside the ExExK motif, and equivalent residues in Cet1 bind a sulfate (Fig. 3b) . The phosphate and sulfate ions presumably mimic substrate phosphate groups. Together with previous findings 21 , these structures show that the pore of Cet1 and the CYTH proteins forms a conserved active site for phosphoryl transfer reactions. In contrast, the pore of Med18 cannot constitute an active site, as residues in the pore are not conserved and the ExExK motif is absent (Fig. 3c) . Furthermore, the Med18 pore is not accessible, as it is closed on one side by the C-terminal helix of Med8 (Figs. 2 and 3 ) and on the other side by the region including helix a1 of Med20 (Fig. 2a) .
Modularity of Med8 in vitro and in vivo
In an attempt to extend the Med8C/18/20 structure to a trimer containing full-length Med8, we coexpressed full-length Med8 with Med18 D109-140 and Med20 from a tricistronic vector in E. coli. A stoichiometric and soluble trimeric complex was obtained but could not be crystallized, indicating flexibility in Med8. Partial proteolysis and sequence analysis suggest that Med8 contains a wellconserved N-terminal helical domain, termed Med8N (Fig. 1b) . Limited proteolysis of individually expressed Med8 followed by Edman sequencing identified a stable 14-kDa fragment, supporting the presence of an independently folded Med8N domain (data not shown). Indeed, Med8N could be purified in soluble form after its overexpression in E. coli (not shown). Med8N is apparently connected to Med8C by a nonconserved, proteolytically sensitive linker (Fig. 1b) . Consistent with an exposed flexible linker, the mammalian Med8 linker sequence contains an interaction element for binding the elongin B-elongin C complex 24 .
To investigate which Med8 regions are required for cell viability, we carried out complementation studies in yeast. We generated plasmids expressing, under the control of the MED8 promoter, full-length Med8 and three Med8 variants with different C-terminal truncations (Fig. 4 ). Plasmids were introduced into a med8D strain rescued by a MED8-encoding URA3 plasmid. Complementation would allow for loss of the URA3 plasmid and growth on media containing 5-fluorotic acid (5-FOA). Complementation was observed with full-length MED8, with med8 1À189 , which lacks Med8C, and with med8 1À138 , which corresponds to Med8N (Fig. 4a) . The plasmid encoding med8 1À94 , predicted to express a disrupted Med8N domain, did not rescue cell growth (Fig. 4a) . Thus, the conserved N-terminal domain Med8N is essential for cell viability, whereas the C-terminal Med18-binding region Med8C and the linker are not. The Med8 linker seems to have an important function in vivo, as the shuffle strain with med8 1À138 , which lacks the linker, showed severely compromised growth (Fig. 4a) .
The essential Med8 N-terminal domain binds TBP Candidate interaction partners of the Med8/18/20 subcomplex include Pol II and general transcription factors, as reconstituted recombinant Mediator head module binds TBP and TFIIB 10 . We therefore tested Med8/18/20 for its ability to bind recombinant His 6 -tagged TBP and TFIIB immobilized on nickel-nitrilotriacetic acid (Ni-NTA) beads (Fig. 5a ). In these assays, we detected clear binding of Med8/18/20 to TBP, but not to TFIIB, the Pol II core or the Pol II subcomplex Rpb4-Rpb7 ( Fig. 5a and not shown), showing that the TBP interaction is specific. To investigate which region of Med8/18/20 is responsible for TBP binding, we tested Med8 and Med8C/18/20 in pull-down assays. Med8C/18/20 did not show detectable TBP binding (data not shown), providing a negative control. In contrast, free Med8 bound strongly to TBP (Fig. 5b) . Further, recombinant Med8N was sufficient for TBP binding (Fig. 5c ), establishing this domain as a TBP-binding submodule of the Mediator head. The protein interactions revealed by our assay are robust and specific, as we used highly soluble and pure recombinant proteins, analyzed bound proteins by direct gel staining rather than by western blotting and used a stringent washing protocol, and because all controls are free of background (Methods and Fig. 5 ).
DISCUSSION
Following our crystal structures of the Med7/21 heterodimer in the Mediator middle module 25 and cyclin C in the kinase module 26 , we provide here structural information on the head module, in particular the Med18/20 heterodimer in free form and bound to the C-terminal region of Med8. The work shows that coexpression of Mediator subunits in E. coli can generate crystallization-grade dimeric and trimeric subcomplexes, and probably higher-order assemblies, that are amenable to high-resolution structure determination by X-ray analysis. The structures can later be used for the interpretation of medium-resolution X-ray crystallographic maps or cryo-EM reconstructions of larger Mediator subcomplexes and eventually MediatorPol II complexes. The results also enabled structure-guided studies in vitro and in vivo, thereby providing insights into the mechanism of Mediator function.
Our results indicate that the Med8/18/20 complex consists of two structurally independent submodules, Med8N and Med8C/18/20 (Fig. 6a) . Whereas Med8N is essential for yeast viability, all three parts of the Med8C/ 18/20 submodule are nonessential, and deletion of any part leads to a similar growth phenotype. The med8 1À189 strain and knockout strains that lack either MED18 or MED20 (also called SRB5 and SRB2, respectively) all showed slow growth at 30 1C and did not grow at 37 1C (Fig. 4b) . The Med8C/18/20 submodule is apparently involved in protein interactions. Analysis of the surface conservation of Med8C/18/20 reveals that one face is well conserved, whereas the other is not (Fig. 6b) . Both Med18 and Med20 contribute to a continuous conserved surface, consistent with a functional Med8C/18/20 submodule. Published data suggest that Med8C/18/20 is involved in interactions that have a positive effect on transcription. Med18 and Med20 are required for stable initiation complex formation 8, 13, 17 , and Mediator-Pol II complex lacking Med18 and Med20 is defective in basal transcription 16 . Expression profiles of yeast strains lacking either MED18 or MED20 are nearly identical and show mainly decreased transcript levels 27 , consistent with a functional Med8C/18/20 submodule that has a positive role in transcription in vivo.
The srb mutations srb2-1 and srb5-1 alter Med20 and Med18, respectively, at sites on the putative proteininteraction face of the Med8C/18/20 submodule; these sites are not involved in stabilizing subunit interfaces or hydrophobic cores (Fig. 6b) . Thus, these two srb mutations probably affect protein interactions of the Med8C/18/20 submodule and do not have structural roles. Med18 and Med20 are products of the SRB5 (or MED18) and SRB2 (or MED20) genes, which were originally identified in a screen for suppressors of the negative effects of CTD truncations 7, 8 . Cells lacking MED20 require a Pol II with 20 of its 26 CTD repeats for viability 17 . However, cells grow normally with only ten CTD repeats in the presence of the srb2-1 suppressor mutation, which changes the Med20 residue Pro14 to a histidine 17 phenotypes are also suppressed by the srb5-1 mutation, which changes the Med18 residue Thr22 to isoleucine 8 . Although the physical basis for rescue of CTD truncation defects by srb mutations remains yet to be understood, our data indicate that srb mutations can influence the strength of protein interactions within the initiation complex. The second submodule in the Med8/18/20 subcomplex, Med8N, binds TBP in vitro and has an essential function in vivo. Sequence analysis reveals that Med8N, together with Med6, forms the most highly conserved region of the Mediator head module (37% sequence similarity between yeast residues 26-129 and human). Protein solubility studies, limited proteolysis and secondary structure prediction suggest that Med8N forms a structured helical domain. Thus, Med8N is a conserved, essential TBP-binding submodule. As Med20 has previously been shown to interact directly with TBP 17 , the TBPbinding site of the Mediator head is apparently multipartite and includes Med8N, Med20 and possibly additional parts of the head module. We did not detect an interaction between TBP and the Med8C/18/20 submodule, which is apparently inconsistent with the published Med20-TBP interaction. However, the sensitivity of our assay is much lower than that of the published protocol, which used western blotting to reveal the protein interaction 17 . Thus, our results do not exclude a Med20-TBP interaction, but they suggest that it is weaker than the Med8-TBP interaction. A direct Mediator head-TBP interaction could partially account for maintenance of a stable scaffold complex that remains at the promoter for multiple rounds of transcription 28 . The Mediator head-TBP interaction is also consistent with a defect in initiation-complex assembly at the promoter in extracts of yeast strains with deletions of MED18 or MED20 (ref. 13 ) and with genome-wide Mediator interactions with promoters that correlate with increased transcription activity 29, 30 .
Published results show that the Mediator-TBP interaction depends on an activator. Binding of the yeast Pol II-Mediator complex to TBP requires that the activator Gal4VP16 is prebound 16 . Gal4VP16 also stabilizes assembly of human Mediator and TBP on DNA 31 , and human Mediator enhances TBP-DNA binding in an activator-dependent manner 32 . Although these results can be explained by simultaneous binding of activator to TBP and Mediator, we suggest an alternative model, namely that activator binding to Mediator results in a modulation and exposure of Mediator's TBP-binding site. The idea of activator-induced TBP site exposure on Mediator is consistent with the small peptide-like size of many activation domains, with recent genome-wide Mediator localization studies that query recruitment models of regulation 30 and with the electronmicroscopic observation of activator-induced large-scale conformational changes in Mediator 33 . Structural changes in Mediator could rely on hinge motions 25 or on a relative repositioning of submodules connected by flexible linkers (Fig. 6b) . In addition, some folds of Mediator subunits may undergo structural changes. For example, the Med20 barrel may open, as observed for the barrel in ORF1496 of Nitrosomonas europaea (PDB entry 2FBL; Fig. 3a) , as it shows some flexibility in our crystals ( Supplementary  Fig. 3 online) .
The Med8/18/20 subcomplex is anchored to the remainder of the head module by contacts of Med8 and Med20 to subunit Med17 (refs. 9,10,18,19) . The strength of the Med20-Med17 interaction is, however, insufficient to retain Med20 within Mediator, as MediatorPol II complex purified from yeast MED18 knockout cells lacks both Med18 and Med20 (ref. 16 ). Accordingly, in vitro transcription with an extract from a med18D strain requires addition of both Med18 and Med20 to restore basal transcription 8 . In contrast, transcription with an extract from a med20D strain requires addition only of Med20 (ref. 17, 34) , showing that the Med8-Med17 interaction is sufficient to retain Med18 in the Mediator complex. Taken together, the Med8-Med17 contact seems to be mainly responsible for tethering Fig. 1b-d) . Residues affected by srb2-1 and srb5-1 mutations 8, 17 are in magenta and blue, respectively.
the Med8/18/20 subcomplex to the remainder of the head module. The transient Med20-Med17 interaction could be relevant for a modulation of Mediator's TBP site. For example, the srb2-1 mutation affecting the Med20 surface could influence the strength of the Med20-Med17 interaction and change TBP-site accessibility (Fig. 6b) .
METHODS
Cloning. We modified pET-24b vectors for bicistronic expression of Med18/20 or tricistronic expression of Med8/18/20 under the control of one T7 promoter (Fig. 1a) . Genes encoding the Mediator subunits were inserted into the vector in the order Med20-Med18 or Med8-Med20-Med18, and ribosomal binding sites and new restriction sites were added (Fig. 1a) . 35, 36 . For protein purification, cells were lysed by sonication in buffer A (20 mM Tris (pH 8.0), 150 mM NaCl, 10 mM b-mercaptoethanol).
After centrifugation, the supernatant was loaded onto a Ni-NTA column (Qiagen) equilibrated with buffer A. The column was washed with 40 ml of buffer A and, for the trimeric complex, was further washed sequentially with 40 ml buffer A containing 20 mM and 50 mM imidazole. Bound proteins were eluted with buffer A containing 300 mM imidazole. For purification of Streptagged proteins, cells were lysed by sonication in buffer B (100 mM Tris (pH 8.0), 150 mM NaCl, 10 mM b-mercaptoethanol). After centrifugation, the supernatant was loaded onto a 1-ml Strep-Tactin column (IBA Tools) equilibrated with buffer B. The column was washed six times with one column volume of buffer B and bound proteins were eluted with buffer B containing 2.5 mM desthiobiotin. All complexes were further purified by anion exchange chromatography (Mono Q, Amersham Biosciences). The column was equilibrated with buffer C (20 mM Tris (pH 8.0), 100 mM NaCl, 5 mM dithiothreitol) and proteins were eluted with a linear gradient of 10 column volumes from 100 mM to 1 M NaCl in buffer C. After concentration, the sample was applied to a Superose-12 size-exclusion column (Amersham) equilibrated with buffer C containing 150 mM NaCl. For crystallization, the complexes were concentrated to 20 mg ml -1 . Rpb4-Rpb7 and TBP were purified as described 37, 38 and TFIIB was purified by Ni-NTA and ion-exchange chromatography (Mono S, Amersham) (K. Armache & P.C., unpublished data).
Crystallization and X-ray structure determinations. Crystals of the Med18/20 heterodimer were grown at 20 1C in hanging drops over reservoirs containing 100 mM Tris (pH 8.5) and a 1.8 M mixture of sodium phosphate and potassium phosphate. Crystals of the trimeric complex Med8C/18/20 were grown at 20 1C in sitting drops over a reservoir containing 100 mM sodium acetate (pH 4.6) and 0.6 M sodium fluoride. Crystals were harvested by gradually adding glycerol to the mother solution to a final concentration of 25% (v/v). Crystals were flash-cooled in liquid nitrogen. Diffraction data were collected at 100 K on a MARCCD 225 detector at the Swiss Light Source, Villigen, Switzerland. For the labeled dimeric complex Med18/20, diffraction data were processed with MOSFLM and SCALA 39 . SOLVE 40 identified 31 selenium sites, which were used for phasing. Solvent flattening, noncrystallographic symmetry averaging and building of an initial protein model were done with RESOLVE 40 . The resulting electron density map allowed for building most of Med18 and Med20 using TURBO-FRODO 41 . The model was refined using the conjugate gradient in the program CNS 42 .
For the trimeric complex Med8C/18/20, diffraction data were processed with DENZO and SCALEPACK 43 . The structure was phased by molecular replacement with PHASER 44 , which positioned four copies of the refined Med18/20 structure in the asymmetric unit. Model bias was removed with high-temperature simulated annealing in CNS. A model-phased difference Fourier map revealed density for the Med8 C-terminal region and some changes in the Med18/20 structure. After rebuilding, the new model was refined with CNS. Owing to the limited resolution and high B-factors in the Med20 structure, noncrystallographic symmetry restraints were maintained during the refinement process, except in clearly divergent areas. Refinement using TLS in REFMAC 45 slightly improved statistics but did not substantially change the coordinates of the structures. For consistency, the CNS-refined models were kept. Both refined structures have low R-factors and good stereochemistry ( Table 1) . Ramachandran plots of the Med18/20 and Med8C/18/20 models show 86.3% and 85.5% of the residues, respectively, in the most favored region and none in disallowed regions 46 .
Yeast manipulations and growth assays. Plasmids pRS316-MED8, pRS316-MED20 and pRS316-MED18 were constructed by amplifying the respective ORF plus 500 base pairs (bp) upstream and 300 bp downstream by PCR, generating BamHI and XhoI sites for MED8 and MED20 and BamHI and HindIII for MED18, and cloning the fragments into the same sites of pRS316. pRS315-MED8, pRS315-med8 1-189 , pRS315-med8 1-138 and pRS315-med8 were constructed by amplifying the MED8 sequence encoding amino acid residues 1-223, 1-189, 1-138 and 1-94, respectively, plus 500 bp upstream, generating BamHI and XhoI sites, and cloning the fragments into the same sites of pRS315-T ADH1 (S.R. and K.S., unpublished data). MED8/med8D, MED18/ med18D and MED20/med20D heterozygous knockout strains were obtained from Euroscarf and transformed with pRS316-MED8, pRS316-MED18 and pRS316-MED20, respectively. Diploids were sporulated and tetrads dissected on YPD plates. To assess the functionality of pRS315-MED8, pRS315-med8 1-189 , pRS315-med8 1-134 and pRS315-med8 , plasmids were transformed into the MED8 shuffle strain. Transformants were restreaked onto 5-FOA. After 6 d on 5-FOA, grown colonies were restreaked on SDC (-Leu). Equal amounts of Highest-resolution shell is shown in parentheses.
